Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
Parkinson’s disease
TREM2
biomarker
cerebrospinal fluid
tau
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
28
06
2019
revised:
26
10
2019
accepted:
11
12
2019
pubmed:
18
2
2020
medline:
7
7
2020
entrez:
18
2
2020
Statut:
ppublish
Résumé
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease and affects 1% of the population above 60 years old. Although Parkinson's disease commonly manifests with motor symptoms, a majority of patients with Parkinson's disease subsequently develop cognitive impairment, which often progresses to dementia, a major cause of morbidity and disability. Parkinson's disease is characterized by α-synuclein accumulation that frequently associates with amyloid-β and tau fibrils, the hallmarks of Alzheimer's disease neuropathological changes; this co-occurrence suggests that onset of cognitive decline in Parkinson's disease may be associated with appearance of pathological amyloid-β and/or tau. Recent studies have highlighted the appearance of the soluble form of the triggering receptor expressed on myeloid cells 2 (sTREM2) receptor in CSF during development of Alzheimer's disease. Given the known association of microglial activation with advancing Parkinson's disease, we investigated whether CSF and/or plasma sTREM2 differed between CSF biomarker-defined Parkinson's disease participant subgroups. In this cross-sectional study, we examined 165 participants consisting of 17 cognitively normal elderly subjects, 45 patients with Parkinson's disease with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia. Stratification of subjects by CSF amyloid-β and tau levels revealed that CSF sTREM2 concentrations were elevated in Parkinson's disease subgroups with a positive tau CSF biomarker signature, but not in Parkinson's disease subgroups with a positive CSF amyloid-β biomarker signature. These findings indicate that CSF sTREM2 could serve as a surrogate immune biomarker of neuronal injury in Parkinson's disease.
Identifiants
pubmed: 32065223
pii: 5739199
doi: 10.1093/brain/awaa021
pmc: PMC7089668
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
TREM2 protein, human
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
932-943Subventions
Organisme : NIA NIH HHS
ID : U24 AG021886
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066515
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG053001
Pays : United States
Organisme : NINDS NIH HHS
ID : P50 NS062684
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS075097
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047366
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS115114
Pays : United States
Informations de copyright
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Alzheimers Dis. 2016 Aug 18;54(1):287-95
pubmed: 27567832
EMBO Mol Med. 2016 May 02;8(5):466-76
pubmed: 26941262
Mol Neurodegener. 2018 Jun 1;13(1):29
pubmed: 29859094
Arch Neurol. 2003 Mar;60(3):387-92
pubmed: 12633150
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477
pubmed: 30564614
J Neuroimmunol. 2007 Mar;184(1-2):92-9
pubmed: 17239445
Acta Neuropathol. 2016 Jun;131(6):925-33
pubmed: 26754641
Nat Immunol. 2009 Jul;10(7):734-43
pubmed: 19503107
Mol Neurodegener. 2019 Jan 10;14(1):1
pubmed: 30630532
Neurology. 2005 Oct 25;65(8):1239-45
pubmed: 16247051
Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
JAMA Neurol. 2013 Feb;70(2):223-8
pubmed: 23407718
J Alzheimers Dis. 2008 Jun;14(2):193-9
pubmed: 18560130
J Biol Chem. 2013 Nov 15;288(46):33027-36
pubmed: 24078628
Brain. 2008 Nov;131(Pt 11):3081-91
pubmed: 18790823
J Alzheimers Dis. 2016 Nov 1;55(1):199-217
pubmed: 27662313
Parkinsonism Relat Disord. 2017 May;38:31-34
pubmed: 28215728
J Immunol. 2006 Aug 15;177(4):2051-5
pubmed: 16887962
J Parkinsons Dis. 2013;3(2):205-14
pubmed: 23938350
Nat Rev Immunol. 2003 Jun;3(6):445-53
pubmed: 12776204
Exp Neurol. 2018 Apr;302:205-213
pubmed: 29407460
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462511
Neurology. 2018 Sep 18;91(12):e1182-e1195
pubmed: 30143564
J Exp Med. 2016 May 2;213(5):667-75
pubmed: 27091843
Acta Neuropathol. 2010 May;119(5):591-600
pubmed: 20306268
Mov Disord. 2010 Nov 15;25(15):2501-7
pubmed: 20878991
Ups J Med Sci. 2012 Aug;117(3):284-92
pubmed: 22554142
Cell. 2017 Aug 10;170(4):649-663.e13
pubmed: 28802038
Brain. 2008 Jul;131(Pt 7):1736-48
pubmed: 18567922
J Neurol. 2019 Sep;266(9):2304-2311
pubmed: 31179518
J Immunol. 2006 Sep 15;177(6):3520-4
pubmed: 16951310
Alzheimers Dement. 2016 Dec;12(12):1259-1272
pubmed: 27423963
N Engl J Med. 2013 Jan 10;368(2):107-16
pubmed: 23150908
Nat Neurosci. 2019 Feb;22(2):191-204
pubmed: 30617257
J Neuroinflammation. 2018 Nov 3;15(1):304
pubmed: 30390679
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Neurology. 2019 Apr 16;92(16):e1821-e1830
pubmed: 30894446
Brain. 2018 Jul 1;141(7):2181-2193
pubmed: 29878075
Neurol Neuroimmunol Neuroinflamm. 2018 Nov 07;6(1):e512
pubmed: 30568991
Mol Neurodegener. 2013 Jun 21;8:19
pubmed: 23800361
Sci Transl Med. 2016 Dec 14;8(369):369ra178
pubmed: 27974666
N Engl J Med. 2013 Jan 10;368(2):117-27
pubmed: 23150934
Mol Neurodegener. 2016 Jan 12;11:3
pubmed: 26754172
Clin Chim Acta. 2019 Jul;494:74-78
pubmed: 30878539
Neurology. 2009 Mar 31;72(13):1121-6
pubmed: 19020293
Ann Neurol. 2019 Jan;85(1):47-58
pubmed: 30485483
Sci Transl Med. 2018 Aug 15;10(454):
pubmed: 30111645
Neuron. 2016 Jul 20;91(2):328-40
pubmed: 27477018
Sci Transl Med. 2014 Jul 2;6(243):243ra86
pubmed: 24990881
Neurobiol Aging. 2013 Jun;34(6):1711.e15-7
pubmed: 23391427
Alzheimers Res Ther. 2016 Apr 27;8(1):17
pubmed: 27121148
World J Biol Psychiatry. 2018 Jun;19(4):244-328
pubmed: 29076399
Neurology. 2005 Nov 8;65(9):1490-2
pubmed: 16275845
Parkinsonism Relat Disord. 2018 May;50:29-36
pubmed: 29478836
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261
J Neural Transm (Vienna). 2006 Mar;113(3):339-45
pubmed: 15997419
Nat Commun. 2019 Mar 25;10(1):1365
pubmed: 30911003
Mov Disord. 2019 Feb;34(2):285-291
pubmed: 30776152